 |
|
The AED (Antiepileptic Drug) Pregnancy Registry
A 6-Year Experience
Lewis B. Holmes, MD;
Diego F. Wyszynski, MD, MHS, PhD;
Ellice Lieberman, MD, DrPH; for the AED Pregnancy Registry
Arch Neurol. 2004;61:673-678.
Background Pregnancy registries are a new method for assessing the fetal risks from exposures in pregnancy. We present the findings of the North American AED (antiepileptic drug) Pregnancy Registry for phenobarbital sodium–exposed pregnancies.
Objective To determine whether exposure during pregnancy to anticonvulsant drugs as monotherapy, and phenobarbital in particular, is associated with an increased risk of major malformations in comparison with unexposed controls.
Design Evaluation of registry data.
Setting The North American AED Pregnancy Registry.
Patients Pregnant women throughout the United States and Canada who were taking an anticonvulsant drug and who called a toll-free telephone number to enroll.
Interventions Each woman was interviewed by telephone at enrollment, at 7 months' gestation, and post partum. With the mother's written permission, her medical records and those of her infant were obtained.
Main Outcome Measures Major malformations identified by 5 days of age. Criteria for the release of findings were established by the independent Scientific Advisory Committee on the basis of malformations identified in infants of women who had enrolled prospectively before having had any prenatal screening ("pure" enrollees).
Results Five (6.5%) of 77 pure pregnancies with exposure to phenobarbital monotherapy were associated with major malformations (95% confidence interval of proportion, 2.1%-14.5%). When compared with the background rate (1.62%), there was a significantly increased risk (relative risk, 4.2; 95% confidence interval, 1.5-9.4).
Conclusions A hospital-based pregnancy registry can establish the fetal risk of major malformations for a commonly used drug. Prenatal exposure to phenobarbital is associated with a significantly increased risk of fetal abnormalities.
From the Genetics and Teratology Unit, Pediatric Service, Massachusetts General Hospital, Boston (Dr Holmes); Department of Pediatrics, Harvard Medical School, Boston (Dr Holmes); Genetics Program, Department of Medicine, Boston University School of Medicine (Dr Wyszynski); and Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston (Dr Lieberman). A listing of the AED Pregnancy Registry staff and its Scientific Advisory Committee appears above.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy
Holmes et al.
Neurology 2008;70:2152-2158.
ABSTRACT
| FULL TEXT
Importance of monotherapy in women across the reproductive cycle
Montouris
Neurology 2007;69:S10-S16.
ABSTRACT
| FULL TEXT
Epilepsy in pregnancy
Tomson and Hiilesmaa
BMJ 2007;335:769-773.
FULL TEXT
Teratogenicity of antiepileptic drugs
Breen and Davenport
BMJ 2006;333:615-616.
FULL TEXT
In utero antiepileptic drug exposure: Fetal death and malformations
Meador et al.
Neurology 2006;67:407-412.
ABSTRACT
| FULL TEXT
Topical Review: Optimizing Epilepsy Management in Teenagers
Sheth and Gidal
J Child Neurol 2006;21:273-279.
ABSTRACT
Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register
Morrow et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:193-198.
ABSTRACT
| FULL TEXT
Current treatments of epilepsy
Nadkarni et al.
Neurology 2005;64:S2-S11.
ABSTRACT
| FULL TEXT
What can we say to women of reproductive age with epilepsy?
Penovich and Gaily
Neurology 2005;64:938-939.
FULL TEXT
Increased rate of major malformations in offspring exposed to valproate during pregnancy
Wyszynski et al.
Neurology 2005;64:961-965.
ABSTRACT
| FULL TEXT
Antiepileptics, pregnancy and the child
DTB 2005;43:13-16.
ABSTRACT
| FULL TEXT
Reproductive health effects and teratogenicity of antiepileptic drugs
Kaplan
Neurology 2004;63:S13-S23.
ABSTRACT
| FULL TEXT
|
